Eli Lilly to acquire obesity drug maker Versanis for $1.9 billion

The deal is Eli Lilly’s latest attempt to capitalize on the weight loss industry gold rush, which was sparked by demand for Novo Nordisk’s Wegovy and Ozempic.

Previous post Dimon says private equity giants are ‘dancing in the streets’ over tougher bank rules
Next post : JPMorgan Chase stock gaining for sixth straight day